Transcatheter pulmonary valve replacement in pediatric patients

Alkashkari, Wail; Albugami, Saad; abbadi, M. R.; Niyazi, Akram; Alsubei, Amani; Hijazi, Ziyadi M

doi:10.1080/17434440.2020.1775578

Cited by 18 publications

(9 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials on self-expandable devices, including the Venus p-valve® (Venus Medtech, Shanghai, China), Harmony® (Medtronic), and Alterra Pre-stent® (with SAPIEN S3) valves, have been carried out. [25][26][27] The first successful implantation of a single self-expandable valve in a patient with a dilated pulmonary trunk was reported by Schievano et al, and the feasibility study has just been completed in the United States and Canada by Medtronic, Inc. 28,29 After a clinical trial of the harmony valve, high procedural success, and safety, with a favourable acute device performance were revealed. The harmony valve is now the solely self-expandable valve that has food and drug administration approval.…”

Section: Discussionmentioning

confidence: 99%

Early results of Pulsta® transcatheter heart valve in patients with enlarged right ventricular outflow tract and severe pulmonary regurgitation due to transannular patch

2022

View full text Add to dashboard Cite

Objective: The purpose of this study is to assess the feasibility, effectivity, and safety of a novel self-expandable valve system, Pulsta® transcatheter heart valve in patients with tetralogy of fallot and severe pulmonary regurgitation after transannular patch repair. Background: Severe pulmonary regurgitation after tetralogy of fallot repair is a life-threatening problem and should be treated by pulmonary valve implantation. Although percutaneous pulmonary valve implantation has been ever increasingly used for this purpose, available balloon-expandable valves have limitations and cannot be used by most patients. Pulsta® transcatheter heart valve is a new self-expandable valve system and offers a new solution to be used in patients with different types of native right ventricular outflow tract geometry. Patients and Methods: Ten patients with severe regurgitation after tetralogy of fallot repair with a transannular patch have been enrolled in the study according to echocardiographic examination. MRI was used in asymptomatic patients to delineate the indication and the right ventricular outflow tract geometry. Pulsta® transcatheter heart valve implantation was performed in ten patients, and preprocedural, procedure, and 6 months follow-up findings of the patients were evaluated. Results: Pulsta® pulmonary valve implantation was performed in ten patients successfully without any severe complications. Valve functions were perfect in six of ten patients, while the others had insignificant regurgitation by echocardiographic examination at the end of 6 months follow-up. Conclusions: This study showed that Pulsta® transcatheter heart valve is a feasible, effective, and safe method in the treatment of severe pulmonary regurgitation due to transannular patch repair in patients with tetralogy of fallot.

show abstract

Section: Discussionmentioning

confidence: 99%

Early results of Pulsta® transcatheter heart valve in patients with enlarged right ventricular outflow tract and severe pulmonary regurgitation due to transannular patch

2022

View full text Add to dashboard Cite

show abstract

“…TPVR currently has a high success rate with favorable safety and prognosis. A 96.2% success rate was reported in a previous meta-analysis [ 23 ]. Data from US clinical trial data, the freedom from 5-year reintervention and reinsertion rates were reported to be were 76 ± 4% and 92 ± 3%, respectively [ 24 ].…”

Section: Transcatheter Pulmonary Valve Replacement In Large Right Ventricular Outflow Tractsmentioning

confidence: 88%

Tissue Engineered Transcatheter Pulmonary Valved Stent Implantation: Current State and Future Prospect

Zhang

Puehler

Seiler

et al. 2022

IJMS

View full text Add to dashboard Cite

Patients with the complex congenital heart disease (CHD) are usually associated with right ventricular outflow tract dysfunction and typically require multiple surgical interventions during their lives to relieve the right ventricular outflow tract abnormality. Transcatheter pulmonary valve replacement was used as a non-surgical, less invasive alternative treatment for right ventricular outflow tract dysfunction and has been rapidly developing over the past years. Despite the current favorable results of transcatheter pulmonary valve replacement, many patients eligible for pulmonary valve replacement are still not candidates for transcatheter pulmonary valve replacement. Therefore, one of the significant future challenges is to expand transcatheter pulmonary valve replacement to a broader patient population. This review describes the limitations and problems of existing techniques and focuses on decellularized tissue engineering for pulmonary valve stenting.

show abstract

“…Under this directive, we have attempted to implant competent PVs in our paediatric patients who have PAs that have reached sizes suitable for the PPV without waiting to reach the age/weight guidelines. PPVI has been performed previously for paediatric patients with repaired RVOTs [ 11 , 12 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…Very few reports have included cases as young as 3.8 years and 13.5 kg using the Melody valve, and these are primarily reported in cases with repaired Fallot or conduits [ 10 , 11 ]. Few cases with PA/IVS have been included in previous reports [ 12 , 13 , 22 ] to be implanted with the Melody valve or less frequently with the SAPIEN valve [ 12 , 17 ]. We have limited data on those cases whether treated initially surgically or percutaneously; the reports also did not describe the following factors in this particular cohort: the age, weight, or size of the valve used.…”

Section: Discussionmentioning

confidence: 99%

Staged Percutaneous Management of Pulmonary Atresia and Intact Interventricular Septum: Stretching the Limits

El-Saiedi

Attia

Hanna

et al. 2023

Journal of Interventional Cardiology

View full text Add to dashboard Cite

Aims. Pulmonary atresia with intact ventricular septum (PA/IVS) can be treated by catheter-based interventions and complemented by various surgical procedures. We aim to determine a long-term treatment strategy to enable patients to be surgery free, depending solely on percutaneous interventions. Methods and Results. We selected five patients from among a cohort of patients with PA/IVS treated at birth with radiofrequency perforation and dilatation of the pulmonary valve. Patients had reached a pulmonary valve annulus of 20 mm or larger on their biannual echocardiographic follow-up, with right ventricular dilatation. The findings, together with the right ventricular outflow tract and pulmonary arterial tree, were confirmed by multislice computerised tomography. Based on the angiographic size of the pulmonary valve annulus, all patients were successfully implanted with either Melody® or Edwards® pulmonary valves percutaneously, regardless of their small weights and ages. No complications were encountered. Conclusion. We managed to stretch the age and weight limitations for performing percutaneous pulmonary valve implantation (PPVI): interventions were attempted whenever a pulmonary annulus size of >20 mm was reached, which was rationalised by the prevention of progressive right ventricular outflow tract dilatation and accommodating valves between 24 and 26 mm, which is enough to sustain a normal pulmonary flow in adulthood.

show abstract

Transcatheter pulmonary valve replacement in pediatric patients

Cited by 18 publications

References 84 publications

Early results of Pulsta® transcatheter heart valve in patients with enlarged right ventricular outflow tract and severe pulmonary regurgitation due to transannular patch

Early results of Pulsta® transcatheter heart valve in patients with enlarged right ventricular outflow tract and severe pulmonary regurgitation due to transannular patch

Tissue Engineered Transcatheter Pulmonary Valved Stent Implantation: Current State and Future Prospect

Staged Percutaneous Management of Pulmonary Atresia and Intact Interventricular Septum: Stretching the Limits

Contact Info

Product

Resources

About